BCOP Updates 2024: Updates in Non-Small Cell Lung Cancer
There have been many recent advances in the treatment of non-small cell lung cancer (NSCLC). This session will focus on recently approved indications, as well as updated efficacy data from prior approvals. The addition of immunotherapy or targeted therapy to chemotherapy in early-stage NSCLC has improved outcomes in a number of recent trials. In addition, many targeted agents have been recently approved for patients harboring specific genetic mutations. Finally, overall survival data has been updated for multiple trials in the NSCLC space. This session will also address adverse effects associated with new agents.
BCOP Updates 2024: Updates in Non-Small Cell Lung Cancer
Author: Erin Kelley, PharmD BCOP
UAN#: 0465-0000-24-090-H01-P
Learning Objectives:
- Describe recent trials examining the addition of immunotherapy to chemotherapy in early stage NSCLC
- Select an appropriate therapy regimen for patients with early stage NSCLC
- Summarize data on approved adjuvant targeted therapies in early stage NSCLC
- Outline the updated published overall survival data for therapies in NSCLC
- Identify patients appropriate for new targeted therapies in late stage NSCLC
- Differentiate adverse effects associated with targeted NSCLC treatments
Get it Now!
Knowledge Course for Pharmacist
Technology requirements: HOPA Learn requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
HOPA is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. In order to claim BCOP credit, you must pass the BCOP Post- Test with a 75% or higher.
All CE hours will be transmitted to the CPE Monitor and BPS within 1-2 weeks of course completion.